Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cancer Cell|May 3, 2024
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?Si-Yang Liu, Wei-Neng Feng, Yi-Long Wu
AI Zheng = Aizheng = Chinese Journal of Cancer|July 12, 2005
[Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions]Chao Cheng, Yi-Long Wu, Li-Jia Gu, et al.
Combinatorial Chemistry & High Throughput Screening|January 2, 2019
Multiple-line Chemotherapy and Tyrosine Kinase Inhibitor Treatment in Patients with Advanced Lung CancerHua Zhang, Jie Yang, Yan-Ming Deng, et al.
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases|August 19, 2003
[The application of needle video-assisted thoracoscopic biopsy in pathologic diagnosis and staging for advanced lung cancer]Li-jia Gu, Yi-long Wu, Wei-neng Feng, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|March 18, 2005
[Treatment of non-small-cell lung cancer with paraplatin given by two different dosage calculation methods]Li-Jia Gu, Yi-Long Wu, Wei-Neng Feng, et al.
Translational Oncology|March 12, 2018
Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC PatientsWei-Neng Feng, Wei-Quan Gu, Ning Zhao, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|May 29, 2012
Concurrent weekly docetaxel chemotherapy in combination with radiotherapy for stage III and IVA-B nasopharyngeal carcinomaWei-Hong Wei, Xiu-Yu Cai, Tao Xu, et al.
World Journal of Surgical Oncology|February 14, 2023
Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trialsNing Zhao, Zhuo-Peng Wu, Jie Yang, et al.
Therapeutic Advances in Medical Oncology|April 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patientsZhen Wang, Xu-Chao Zhang, Wei-Neng Feng, et al.
Clinical Lung Cancer|December 25, 2024
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System DiseaseChang Lu, Hong-Hong Yan, Chan-Yuan Zhang, et al.
Pageof 2